spirostane | 6173-22-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: spirostane
• 英文别名: Spirostan；(1R,2S,4S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]
• CAS: 6173-22-4
• 化学式: C₂₇H₄₄O₂
• 分子量: 400.645
• InChiKey: INLFWQCRAJUDCR-LHVCHFHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  29
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
  申请人：University of Maryland, Baltimore

  公开号：US10179145B2

  公开（公告）日：2019-01-15

  A hemostatic tissue sealant sponge and a spray for acute wounds are disclosed. The sponge comprises hydrophobically modified polymers that anchor themselves within the membrane of cells in the vicinity of the wound. The seal is strong enough to substantially prevent the loss of blood inside the boundaries of the sponge, yet weak enough to substantially prevent damage to newly formed tissue upon recovery and subsequent removal of the sponge. In examples, the polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The spray comprises hydrophobically modified polymers that form solid gel networks with blood cells to create a physical clotting mechanism to prevent loss of blood. In an example, the spray further comprises at least one reagent that increases the mechanical integrity of the clot. In another example, the reagent prevents microbial infection of the wound.

  本发明公开了一种止血组织密封剂海绵和一种用于急性伤口的喷雾剂。该海绵由疏水改性聚合物组成，可将自身锚定在伤口附近的细胞膜内。这种密封性足够强，可基本防止海绵边界内的血液流失，但又足够弱，可基本防止在恢复和随后移除海绵时对新形成的组织造成损害。举例来说，聚合物本身可防止微生物感染，并适用于正常伤口新陈代谢过程中所需的氧气传输。喷雾剂包括疏水性改性聚合物，可与血细胞形成固体凝胶网络，形成物理凝结机制，防止血液流失。在一个例子中，喷雾剂还包括至少一种试剂，可增加凝块的机械完整性。在另一个例子中，试剂可防止伤口受到微生物感染。
• Body cavity foams
  申请人：Friedman Doron

  公开号：US20050271598A1

  公开（公告）日：2005-12-08

  The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.

  本发明涉及一种不含酒精的化妆品或治疗泡沫载体，由水、疏水性有机载体、泡沫佐剂、表面活性剂和胶凝剂组成。该化妆品或治疗用泡沫载体不含脂肪醇，因此无刺激性且不干燥。这种不含酒精的泡沫载体适合加入水溶性和油溶性治疗剂和化妆品。
• Steroid kit and foamable composition and uses thereof
  申请人：Friedman Doron

  公开号：US20060018937A1

  公开（公告）日：2006-01-26

  A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof.

  一种组合物和治疗包，包括一个气雾剂包装组件，其中包括一个容纳加压产品的容器和一个能够以泡沫形式释放可发泡组合物（包括类固醇）的出口。加压产品包括可发泡组合物，其中可发泡组合物包括：容纳加压产品的容器；以及能够将加压产品作为泡沫释放的出口；其中加压产品包括可发泡组合物，其中可发泡组合物包括： i. 类固醇； ii. 至少一种有机载体，选自由疏水性有机载体、极性溶剂、润肤剂及其混合物组成的组，浓度为约 2%至约 50%（按重量计）； iii.约 0.01%至约 5%（按重量计）的至少一种聚合物添加剂，该聚合物添加剂选 自生物粘合剂、胶凝剂、成膜剂和相变剂组成的组； v. 水；以及 vi. 液化或压缩气体推进剂，其浓度约为总组合物的 3%至约 25%（按重量计）。该组合物还可包括一种治疗活性泡沫佐剂，选自脂肪醇、脂肪酸、羟基脂肪酸及其混合物组成的组。
• BODY CAVITY FOAMS
  申请人：Foamix Ltd.

  公开号：EP1768648A1

  公开（公告）日：2007-04-04
• STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF
  申请人：Foamix Ltd.

  公开号：EP1890679A2

  公开（公告）日：2008-02-27